Comparative Pharmacology
Head-to-head clinical analysis: OLANZAPINE AND FLUOXETINE HYDROCHLORIDE versus UZEDY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OLANZAPINE AND FLUOXETINE HYDROCHLORIDE versus UZEDY.
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE vs UZEDY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI). The combination modulates serotonergic and dopaminergic pathways to treat depressive episodes in bipolar I disorder.
Atypical antipsychotic; antagonist at dopamine D2 and serotonin 5-HT1A/5-HT2A receptors; partial agonist at serotonin 5-HT1A receptors
Olanzapine 6 mg / fluoxetine 25 mg orally once daily in the evening, with dose adjustments based on response and tolerability.
UZEDY (risperidone) extended-release injectable suspension: 75 mg, 100 mg, 150 mg, or 200 mg IM gluteal injection every 2 weeks after a single oral dose of 2 mg risperidone for 2 days; or 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, or 150 mg IM every 4 weeks after oral overlap for 2 days. Oral risperidone may be omitted if patient is stable on oral risperidone 2 mg/day.
None Documented
None Documented
Olanzapine: 30 h (young adults); 50 h (elderly). Fluoxetine: 4-6 days (single dose), 4-6 days (norfluoxetine); longer with chronic dosing (up to 6-8 weeks to steady state). Clinical context: drug accumulates over weeks.
Terminal half-life approximately 30 days (range 23–37 days) after subcutaneous injection, supporting monthly dosing.
Olanzapine: ~57% renal (metabolites), ~30% fecal. Fluoxetine: ~80% renal (metabolites, mainly norfluoxetine), ~15% fecal.
Primarily renal: 80% as metabolites, 1% unchanged. Biliary/fecal: 20%.
Category A/B
Category C
Atypical Antipsychotic
Atypical Antipsychotic